Castle Biosciences Stock Price, News & Analysis

Castle Biosciences (Nasdaq: CSTL) announced that its founder, president and CEO Derek Maetzold has been named CEO of the Year by The CEO Magazine, selected from 586 applicants in their 2025 Executive of the Year Awards program.

Under Maetzold's leadership, Castle has evolved from a startup into a leading diagnostics company with nearly 800 employees. The company has developed proprietary tests for skin cancers, Barrett's esophagus, and uveal melanoma. Castle has also earned recognition as a Top Workplace USA for four consecutive years, reflecting its strong people-first culture and values-driven approach to corporate growth.

Castle Biosciences (Nasdaq: CSTL) has been named a Greater Pittsburgh Top Workplace by The Pittsburgh Post-Gazette, based on anonymous employee feedback. The recognition evaluates workplace culture factors including employee support, growth opportunities, and empowerment.

The company has garnered multiple workplace accolades in 2025, including Top Workplaces USA (fourth consecutive year), ranking third in the Healthcare Industry category, and receiving five Culture Excellence Awards for Innovation, Work-Life Flexibility, Compensation & Benefits, Leadership, and Purpose & Values.

Castle Biosciences (Nasdaq: CSTL) has been recognized in Newsweek's inaugural America's Greatest Companies 2025 list. The company, which specializes in innovative molecular testing for patient care, was selected among 650 U.S. companies based on four key criteria: financial strength, workforce dedication, innovation, and commitment to environmental sustainability and corporate ethics.

The evaluation process incorporated company reviews, SEC filings, USPTO data, and third-party sources to objectively assess corporate performance. CEO Derek Maetzold highlighted the company's 'people first' approach, emphasizing their focus on developing pioneering molecular tests and fostering an innovative corporate culture.

Castle Biosciences (Nasdaq: CSTL) announced new data for their TissueCypher Barrett's Esophagus test to be presented at the American Foregut Society's 2025 Annual Meeting. The study of 85 patients revealed that TissueCypher identified 15% of patients with non-dysplastic Barrett's esophagus (NDBE) as having intermediate or high risk of progression to cancer, despite their seemingly low-risk pathology results.

The study showed patients with intermediate-risk scores had a 9% median five-year progression probability, while high-risk scores indicated a 16% probability. These rates exceed the 8.5% five-year risk threshold associated with low-grade dysplasia, where guidelines recommend more frequent surveillance or treatment. The findings demonstrate TissueCypher's ability to provide more precise risk assessment beyond standard pathology, potentially enabling personalized treatment strategies for preventing esophageal cancer.

Castle Biosciences (Nasdaq: CSTL) announced the publication of two significant studies validating their DecisionDx-SCC test for high-risk cutaneous squamous cell carcinoma (SCC). The first study demonstrated the test's ability to predict local recurrence in National Comprehensive Cancer Network (NCCN) high-risk patients post-Mohs surgery, adding to its existing capabilities of predicting metastasis risk and response to adjuvant radiation therapy (ART).

The studies showed that DecisionDx-SCC significantly outperformed traditional staging systems, with three-year local recurrence-free survival rates of 95.3% (Class 1), 85.5% (Class 2A), and 71.4% (Class 2B). The test demonstrated superior predictive accuracy when combined with clinicopathologic factors, providing clinicians with actionable decision points for treatment planning.

Castle Biosciences (Nasdaq: CSTL), a healthcare diagnostics company, announced its participation in three upcoming investor conferences in September 2025. The company will present at Baird's 2025 Global Healthcare Conference on September 10 at 10:15 a.m. Eastern time, with a live webcast available on their investor relations website.

Additionally, Castle's management will be available for one-on-one meetings during the Wells Fargo Healthcare Conference on September 4 and the Lake Street Best Ideas Growth Conference on September 11. Meeting requests must be coordinated through Wells Fargo and Lake Street Capital Markets.

Castle Biosciences (Nasdaq: CSTL) reported Q2 2025 financial results with revenue of $86.2 million. The company delivered 26,574 total test reports, a 6% increase year-over-year, with core tests DecisionDx-Melanoma and TissueCypher showing strong 33% combined growth.

Key developments include FDA Breakthrough Device designation for DecisionDx-Melanoma, acquisition of Previse, and a collaboration with SciBase. The company raised its full-year 2025 revenue guidance to $310-320 million from $287-297 million. Q2 net income was $4.5 million with gross margin at 77%.

Notable impacts include Novitas LCD affecting DecisionDx-SCC coverage and the discontinuation of IDgenetix in May 2025. The company maintained a strong financial position with $275.9 million in cash and investments as of June 30, 2025.

Castle Biosciences (Nasdaq: CSTL), a healthcare company specializing in innovative diagnostic tests, has announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference. The company's executive management will deliver a corporate overview presentation on Tuesday, August 12, 2025, at 12:30 p.m. Eastern time.

Investors and interested parties can access the live audio webcast through Castle Biosciences' investor relations website at ir.castlebiosciences.com/events-presentations/. A replay of the presentation will be made available after the event.

Castle Biosciences (Nasdaq: CSTL) announced that its founder, president and CEO Derek Maetzold has been named a 2025 Most Admired CEO by the Houston Business Journal. The award recognizes CEOs who demonstrate exceptional leadership, vision and values in Houston's leading organizations.

The recognition highlights Maetzold's leadership in building Castle Biosciences into a company focused on developing innovative diagnostic tests for skin cancers, Barrett's esophagus and uveal melanoma. The company's CFO Frank Stokes praised Maetzold's nearly two-decade tenure for creating a patient-centered culture and driving meaningful progress in personalized disease insights.